{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-049083","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.285577+00:00","generated_at":"2026-06-09T16:17:07.206274+00:00","sec_items":["8.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"Catalyst announces CSRC approval for business combination with Beijing Continent","bullets":["Beijing Continent Pharmaceuticals received CSRC approval on Oct 20, 2023 for the business combination.","Business Combination Agreement dated Dec 26, 2022, as amended, involves Catalyst and GNI entities.","Parties anticipate completion by the outside date as defined in the agreement.","Closing remains subject to satisfaction of other conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-049083","json":"https://secwatch.observer/filing/0001140361-23-049083.json","markdown":"https://secwatch.observer/filing/0001140361-23-049083.md","text":"https://secwatch.observer/filing/0001140361-23-049083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123049083/0001140361-23-049083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123049083/ef20012969_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T16:17:07.206274+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}